Followers | 3192 |
Posts | 155370 |
Boards Moderated | 4 |
Alias Born | 06/03/2011 |
Tuesday, June 20, 2023 12:30:55 PM
$SONN CEO Update pic.twitter.com/LCmL6m7dup
— DRAX$ 🇺🇸🇪🇺🇮🇱 (@Jay93231852) June 20, 2023
Recent SONN News
- Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment • GlobeNewswire Inc. • 11/12/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2024 01:30:38 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 11/07/2024 02:22:40 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/07/2024 05:15:13 AM
- Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 11/06/2024 06:20:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/06/2024 02:22:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2024 01:48:59 PM
- Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates • GlobeNewswire Inc. • 11/06/2024 01:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/04/2024 02:01:21 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/28/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2024 12:50:32 PM
- Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq • GlobeNewswire Inc. • 10/17/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/09/2024 12:56:20 PM
- Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India • GlobeNewswire Inc. • 10/09/2024 12:45:00 PM
- Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs • GlobeNewswire Inc. • 10/04/2024 12:30:00 PM
- Sonnet BioTherapeutics Announces Launch of CEO Corner Platform • GlobeNewswire Inc. • 09/30/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/30/2024 12:30:28 PM
- Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split • GlobeNewswire Inc. • 09/25/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2024 12:36:17 PM
- Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors • GlobeNewswire Inc. • 09/18/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 09:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:08:40 PM
- Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series • GlobeNewswire Inc. • 09/04/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 12:30:39 PM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM